The Rise of Synthetic Biology: A New Paradigm in the Biotech Industry by 2026
Editor
Synthetic Biology: The New Engine of the 21st Century Industrial Revolution
As of 2026, synthetic biology has emerged beyond mere scientific curiosity to become a core technology fundamentally reshaping the global industrial ecosystem. According to the latest report by McKinsey & Company, the synthetic biology market is projected to reach approximately $85 billion, a 47% increase from 2025, and is expected to expand to $390 billion by 2030 with a compound annual growth rate (CAGR) of 32%. This explosive growth is driven by the sharp decline in DNA synthesis costs and advancements in AI-based biological design tools. Currently, DNA synthesis costs have decreased by about 70% compared to 2020, demonstrating a pace of technological advancement reminiscent of Moore’s Law in the semiconductor industry.
Notably, synthetic biology is completely transforming the paradigms of existing chemical and pharmaceutical industries. Chemical production, traditionally reliant on petrochemical processes, is now being replaced by fermentation processes using customized microorganisms. Amyris (NASDAQ: AMRS), headquartered in Emeryville, California, is one of the leading companies in this transformation, producing a variety of products from cosmetic ingredients to biofuels using yeast. In its Q4 2025 performance, Amyris reported revenues of $215 million, a 34% increase from the same period the previous year, with over 80% of this revenue generated from synthetic biology-based products.
In the Korean market, investment and interest in synthetic biology are also surging. Samsung Biologics (KOSPI: 207940), headquartered in Songdo, Incheon, announced its official entry into this field with the completion of a dedicated synthetic biology R&D center by the end of 2025. Samsung Biologics plans to invest approximately 800 billion won over the next five years to build capabilities in synthetic biology-based drug development and bio-chemical production. Additionally, Celltrion (KOSPI: 068270) announced the establishment of a synthetic biology research lab in Boston, USA, in early January 2026, aiming to secure competitiveness in the global biotech hub.
The most innovative aspect of synthetic biology is the ability to program living organisms like software. Ginkgo Bioworks (NYSE: DNA), headquartered in Boston, is a representative company that has realized this concept, establishing a unique business model as a “platform company for biology.” Ginkgo Bioworks provides services to design and produce customized microorganisms according to customer needs, recording a revenue of $472 million in 2025, an 89% increase from the previous year. Notably, the company’s revenue structure is shifting from one-time project orders to royalty-based long-term contracts. As of the end of 2025, royalty income accounted for 42% of Ginkgo Bioworks’ total revenue, indicating the establishment of a stable and predictable revenue base.
The applications of synthetic biology are astonishingly diverse. In the pharmaceutical sector, technologies that produce complex natural product drugs, previously impossible with chemical synthesis, through microorganisms are becoming commercialized. Roche, headquartered in Basel, Switzerland, announced that over 60% of its anticancer drug ingredients would be produced through synthetic biology-based processes by 2025, achieving an average production cost reduction of 35%. Innovation is also occurring in the agricultural sector. Technologies that reduce the use of chemical fertilizers by utilizing genetically modified microorganisms with nitrogen-fixing capabilities are being commercialized, gaining attention as a new solution for sustainable agriculture.
Market Dynamics and Competitive Landscape Changes
The competitive landscape of the synthetic biology market is characterized by fierce competition between traditional biotech companies and new platform companies. Leading companies in the market can be broadly categorized into three types. The first type includes platform companies like Ginkgo Bioworks, which adopt a B2B model providing synthetic biology tools and services to various industries. The second type includes companies like Amyris and Zymergen, specialized in producing specific products, and the third type involves traditional pharmaceutical companies internalizing synthetic biology technologies.
The most notable trend recently is the convergence of AI and synthetic biology. Since DeepMind’s AlphaFold technology revolutionized protein structure prediction, the role of AI in biological design processes has been rapidly expanding. Zymergen (NASDAQ: ZY), headquartered in Seattle, USA, developed a technology that automates the microbial improvement process using machine learning algorithms, enabling the development of high-performance microorganisms at a speed 10 times faster than before. Zymergen’s R&D expenditure in 2025 amounted to $187 million, representing 34% of its revenue, significantly exceeding the industry average of 22%.
Korean companies are also actively participating in this global competition. SK Bioscience (KOSPI: 302440), headquartered in Pangyo, signed an agreement in November 2025 to establish a joint synthetic biology research center with MIT in the USA, announcing plans to invest 250 billion won over the next three years in developing next-generation vaccines and therapeutics. SK Bioscience’s CEO, Kim An-guk, emphasized, “Synthetic biology is a game-changer that will completely transform the bio industry,” and stated, “Now is the golden time for investment to compete with global top-tier companies.”
From an investment perspective, the synthetic biology field entails significant growth potential along with considerable risks. According to PwC’s analysis, venture capital investment in the synthetic biology sector in 2025 increased by 73% from the previous year, reaching $12.7 billion. Notably, the focus of investment is shifting from early-stage companies to commercialization-stage companies. Series B and later-stage investments accounted for 68% of total investments, indicating that synthetic biology technology is entering a stage of market validation beyond the laboratory.
However, the challenges faced by synthetic biology companies are not insignificant. The most significant issue is the complexity and uncertainty of the technology. Biological systems are more difficult to predict compared to chemical or physical systems, and technologies that succeed in the laboratory often fail in large-scale production. In fact, a survey revealed that about 23% of synthetic biology startups in 2025 encountered technical limitations at the commercialization stage, leading to a change or cessation of business direction. While this uncertainty poses a risk for investors, it also serves as a barrier to entry and provides a competitive advantage for successful companies.
The regulatory environment is also an important variable that synthetic biology companies must consider. The US FDA released new guidelines for synthetic biology products in September 2025, requiring stricter safety evaluations than existing biopharmaceutical regulations. The European Union also announced plans to introduce an integrated regulatory framework for synthetic biology products in the first half of 2026. The Korean Ministry of Food and Drug Safety is also establishing a dedicated organization for the approval of synthetic biology products by December 2025, aligning with global regulatory trends.
Future Prospects and Investment Opportunities
The future of synthetic biology is likely to be determined by the balance between technological maturity and market acceptance. According to the latest analysis by Boston Consulting Group, 2026 is expected to be a turning point where synthetic biology moves from the “valley of technological innovation” to the “hill of commercial diffusion.” As synthetic biology-based products in the chemical, agricultural, and pharmaceutical sectors begin to show clear competitive advantages over existing products, large-scale market adoption is anticipated to accelerate. Indeed, a survey revealed that 78% of global chemical companies plan to adopt synthetic biology-based production processes within the next five years.
From a sustainability perspective, the value of synthetic biology is becoming more pronounced. Recognized as a key technology for achieving carbon neutrality goals, investment from governments and companies is significantly increasing. The US Department of Energy announced plans to invest $2.3 billion in synthetic biology-based biofuel research in 2026, a 45% increase from the previous year, and the European Union also announced support of €1.8 billion for synthetic biology projects as part of the Green Deal policy. The Chinese government also designated synthetic biology as a strategic emerging industry in its 14th Five-Year Plan, announcing plans to invest approximately 15 billion yuan (about $2.1 billion) in 2026 alone.
From an investor’s perspective, the synthetic biology field requires a selective approach. Given the high technological uncertainty, investments in companies with a strong IP portfolio and a proven business model are considered advantageous. Particularly, platform companies are evaluated as relatively stable investment targets as they can diversify risks by securing a wide range of clients. Goldman Sachs biotech analysts advise, “In the synthetic biology field, commercialization capability will be a more important differentiating factor than technological prowess,” and recommend focusing on companies with market-validated products.
For Korean companies, positioning within the global value chain is a crucial task. Existing bio giants like Samsung Biologics and Celltrion are adopting strategies to expand their business areas through synthetic biology, which is expected to yield significant synergy effects. On the other hand, companies like SK Bioscience, which aim to leverage synthetic biology as a new growth engine, will find global partnerships and technological collaboration to be the keys to success. According to the Korea Biotechnology Industry Organization, the number of domestic companies related to synthetic biology increased by 34% compared to 2025, reaching 247 companies, with 85% of them being startups, which is noteworthy.
In conclusion, synthetic biology is currently the most dynamic field in the biotech industry as of 2026. As technological maturity increases and commercial validation cases multiply, the interest of investors and companies is rapidly growing. However, risk factors such as high technological complexity and regulatory uncertainty still exist. Therefore, when considering investment or business entry into this field, a cautious approach that comprehensively reviews technological superiority, commercialization capability, and market positioning is necessary. The impact of synthetic biology on the global industrial ecosystem over the next five years will be beyond imagination, and it will present tremendous opportunities for companies and investors who accurately read and respond to this wave of change.
—
**Disclaimer**: This analysis is written for informational purposes only and is not intended as investment advice or a recommendation for trading. Investment decisions should be made based on individual judgment and responsibility, and no liability is assumed for investment losses based on this content.
